|
Patent landscape, scope, and claims: |
Patent 8,309,572 (US8309572): scope and claims map for topical inhibitors of acetylcholine binding (incl. M3) and where generics/biosimilars face IP barriers
US 8,309,572 claims methods of inhibiting acetylcholine binding to an acetylcholine receptor (claim 1) and specifically to the M3 muscarinic acetylcholine receptor (claims 21+) in humans, where the key operational constraints are: (i) a compound of Formula (I) with broad Markush-style substituent ranges, (ii) topical application, and (iii) optional but increasingly narrower routes and anatomical sites, including respiratory tract delivery via inhalation. The claim set is written so infringement can attach to use/administration rather than to manufacture of the active or composition.
The independent claims are method-of-use and thus the “landscape” risk is less about manufacturing process patents and more about whether later entrants’ products either (a) use the same Formula (I) compound(s) in the claimed way or (b) conduct Paragraph IV challenges aimed at invalidating or carving out the method scope (topical use, M3-selectivity, inhalation route, or specific substituent ranges).
What does US 8,309,572 claim: method-of-use inhibiting acetylcholine binding by topical application?
Claim 1 scope in one line
A topical method for inhibiting acetylcholine binding to an acetylcholine receptor in a human using an effective amount of a Formula (I) compound, where the compound is broadly defined and the contact with the receptor is “by topical application.”
Key claim1 elements that drive infringement
- Biological target
- “acetylcholine receptor in a human” (broad receptor group).
- Pharmacologic mechanism
- “inhibiting the binding of acetylcholine to [the receptor].”
- Drug substance constraint
- “compound of Formula (I)” with substituent variables:
- R1 = R2
- R3 selected from: F, G, H, K, L (each of these is then associated with a substituent class in the claim text)
- L is independently selected from hydrogen, halogen, C1–4 alkyl, halosubstituted C1–4 alkyl, hydroxy-substituted alkyl, and C1–4 alkoxy
- R4/R5 independent from hydrogen, halogen, C1–4 alkyl, aryl, —C1–4 alkyl aryl, cyano, nitro, —(CR7R7)pORb, and (CR7R7)pNRbRb
- R6: hydrogen or C1–4 alkyl
- m: 1–15
- t: 0 or 1–5
- p: 0–4
- Rb: hydrogen, C1–4 alkyl, aryl, C1–4 alkyl aryl
- R7: hydrogen, C1–4 alkyl, halosubstituted C1–4 alkyl, hydroxy-substituted C1–4 alkyl
- X−: pharmaceutically acceptable anion
- Route/formal exposure constraint
- “topical application to said human”
- Therapeutic utility (later claims)
- Treatment uses are expressly tied to respiratory indications (claims 36+), but claim 1 itself is mechanism/route driven.
Claim 2–4 anion narrowing
Claim 2 lists a broad set of pharmaceutically acceptable anions including chloride, bromide, iodide, salts like acetate, fumarate, citrate, tartrate, oxalate, succinate, and aromatic/acid salts like mandelate, methanesulfonate, p-toluenesulfonate.
- Claim 3: bromide
- Claim 4: iodide
This structure supports enforcement even if a later product changes the counterion, unless the modification falls outside the anion set or outside Formula (I) more generally.
How broad is Formula (I) inside US 8,309,572? What substituent ranges matter most?
Formula (I) as claimed is a classic Markush framework with multiple degrees of freedom. For patent scope, the practical question is not the exact drawn scaffold, but which variable combinations are allowed and therefore whether competitors must design around by:
- changing the core architecture (if outside Formula I), or
- changing variable group assignments so they are outside at least one required variable range, or
- avoiding the claimed topical receptor-contact mode.
Most impactful variables (from a design-around standpoint)
- m (1–15): a long range. This gives broad coverage of chain/linker/alkyl-length analogs depending on the scaffold definition.
- t (0–5) and p (0–4): these widen the allowable substitution density and heteroatom-containing substituent patterns.
- R4/R5: includes not only small groups but also aryl and substituted aryl-like motifs plus (CR7R7)pORb and (CR7R7)pNRbRb.
- R3 and L selections: multiple halogen and hydroxy/alkoxy variants.
- X− anion set: broad list supports salt variants.
Convergence into the narrower dependent claim set
Dependent claims add specific parameter selections, but because they still start from the broad Formula (I) definition, they function as fallback positions that preserve enforceability even if a competitor picks some non-overlapping substituent pattern. Claim narrowing examples in your text include:
- Claim 5: m 1–5; t 0–2; p 0–2; R6 hydrogen/C1–4 alkyl; Rb hydrogen/C1–4 alkyl; R7 hydrogen/C1–4 alkyl
- Claim 11: m is 2/3/4
- Claim 13: m 2 and t 1
- Claim 14: m 2, t 1, and R2 and R3 both phenyl, R4 and R5 both hydrogen
- Claim 16 and 53: substituent sets restricted to hydrogen, halogen, methyl, methoxy
- Claim 17: p is 0
- Claim 18: R7 is hydrogen
- Claim 19–20, 27–35: anatomical site and inhalation device/routings
What patents protect M3-specific acetylcholine binding inhibition under US 8,309,572?
Claim 21 is the key independent M3 claim
Claim 21 recasts the same Formula (I), topical contact requirement, and mechanism into:
- inhibition of acetylcholine binding to M3 muscarinic acetylcholine receptor in a human
- contacting is by topical application
Claim 25–31 tighten to respiratory tract and inhalation
- Claim 25: binding in respiratory tract
- Claim 27: M3 receptor contact in respiratory tract
- Claim 28: contact via inhalation by mouth or nose
- Claim 31: inhalation from a medicament dispenser:
- reservoir dry powder inhaler (DPI)
- multi-dose dry powder inhaler
- metered dose inhaler (MDI)
This “device class” language is important. It attempts to cover both powder and aerosolized inhalation modalities, which can matter in generic risk assessments if challengers argue product delivery is not within “inhalation” or not within the enumerated dispenser types.
Claim 29–30 are further route slicers
- Claim 29: via mouth
- Claim 30: via nose
Claim 32 ties M3 binding inhibition to specific respiratory indications
Useful in infringement mapping because it narrows to clinically recognizable uses:
- chronic obstructive lung disease
- chronic bronchitis
- asthma
- chronic respiratory obstruction
- pulmonary fibrosis
- pulmonary emphysema
- allergic rhinitis
Claim 36 also ties the broader acetylcholine receptor inhibition method to the same indication set, and claim 37–41 pick sub-indications.
How strong is the patent estate for competing acetylcholine/M3 binding inhibitors?
A patent “estate” analysis for US 8,309,572 cannot be completed from your supplied text alone because it requires:
- the full bibliographic record (priority application, continuations/divisionals, related filings),
- the complete set of asserted/related US patents (family members),
- and the Orange Book entries / FDA reference product linkage.
Under the constraints here, a complete landscape of other US patents that cover the same Formula (I) compounds, related formulations, and alternative routes cannot be produced accurately.
What can be concluded strictly from the claim text is where the enforceability sits:
- enforcement targets method-of-use for topical receptor-contact inhibition,
- with strong focus on respiratory tract inhalation routes and device categories (claims 19–21, 25–35),
- with fallback layers on specific substituent selections and counterions (claims 2–4, 5, 11–18, 43, 44–48, 49–55).
So the practical strength is highest against competitors who:
- use the same Formula (I) compound class,
- deliver it to the respiratory tract by inhalation (mouth or nose),
- and use salt forms within the enumerated X− set.
Where do generic entry risks arise for topical acetylcholine/M3 inhibitors under these claims?
Risk driver 1: topical application is not limited to a composition type
The claims do not require a particular formulation beyond topical delivery. If a generic or competitor launches a product with the same active compound and delivers it via inhalation meeting “topical contact,” it can meet the route element even if the dosage form is reformulated.
Risk driver 2: claims cover both broad and narrow M3 respiratory use
- Broad coverage: claim 21 (M3) and claim 25/27 (respiratory tract).
- Narrow coverage: claims 28–31 (inhalation and device classes).
This creates a staircase that can trap multiple launch scenarios:
- If a generic product argues it delivers differently (e.g., not mouth or nose), claims 30–31 still reach “mouth” and “nose” separately.
- If it argues it is not a DPI/MDI, the claims only cover “medicament dispenser selected from” those types, so a non-listed dispenser could be a design-around path. However, infringement could still exist under broader “inhalation” elements in claims 28–30 depending on how a product is characterized.
Risk driver 3: substituent-range flexibility makes “active redesign” harder
Because the Formula (I) ranges span:
- m 1–15,
- t 0–5,
- p 0–4,
- broad aryl/alkyl and heteroatom-containing substituent options on R4/R5,
a competitor that selects a nearby analogue but keeps the same core scaffold and variable choices likely remains within Formula (I). Launch risk is highest where a competitor selects a “close” analogue rather than a chemically non-equivalent structure outside Formula (I).
How might challengers attack US 8,309,572 claims (and where are the likely fault lines)?
This section maps claim vulnerabilities based on the claim architecture you provided, not on case-specific docket data.
Likely challenge points in method-of-use claims
- “topical application” interpretation: whether an inhalation delivery is a “topical application” to the receptor in the claimed legal sense depends on claim construction, which may hinge on whether receptor contact is at the site of administration (respiratory mucosa) versus systemic exposure.
- “inhibiting the binding”: infringement often turns on whether the product mechanistically inhibits acetylcholine binding to the receptor at the relevant site. Competitors may attempt to differentiate via pharmacodynamics, but method-of-use claims can still be asserted based on product capability.
- Formula (I) coverage: most direct non-infringement path is to choose an active outside Formula (I). The broad Markush ranges increase the odds that “near neighbors” still fall within scope.
- Counterion: narrowing to certain anions appears in dependent claims (claims 2–4, 22–24, 42), so changing the salt may only reduce exposure to those dependent claims. Independent claim 1 and 21 still require “pharmaceutically acceptable anion X−,” so a non-enumerated anion could still qualify if it is “pharmaceutically acceptable,” depending on construction and the specification.
Claim chart style breakdown (high-level) for infringement mapping
| Claim element |
Claim 1 (general receptor) |
Claim 21 (M3) |
Dependent narrowing in your text |
| Target |
acetylcholine receptor |
M3 muscarinic receptor |
None to target beyond M3 |
| Mechanism |
inhibits acetylcholine binding |
inhibits acetylcholine binding |
None |
| Drug |
Formula (I) compound |
Formula (I) compound |
Various R-group restrictions (11–18, 43–55) |
| Counterion |
pharmaceutically acceptable X− |
pharmaceutically acceptable X− |
bromide/iodide enumerated (2–4, 22–24, 42) |
| Route |
topical application |
topical application |
respiratory tract + inhalation + dispenser class (19–20, 25, 27–31) |
| Indication |
(in claims 36+ via 36) |
(in claim 32 via 32+) |
specific disease picklist (37–41) |
What dosage forms and delivery devices are implicated by US 8,309,572?
Inhaler/device coverage
The explicit enumerations are in claim 31 for the inhalation delivery system:
- reservoir dry powder inhaler
- multi-dose dry powder inhaler
- metered dose inhaler
Therefore, competitor products that are otherwise within Formula (I) and delivered to the respiratory tract by inhalation using these device types are in the highest risk bucket.
Respiratory tract coverage
Claims 19 and 25 and 27 lock the anatomical site:
- respiratory tract
- inhalation by mouth or nose
How does US 8,309,572 compare with other method-of-use patents for muscarinic/acetylcholine pathway assets?
Without the rest of the file or the chemical identity, the most defensible comparison is structural:
- Many muscarinic patent estates cover antagonists/agonists through receptor subtype and indication.
- This patent adds a special axis: acetylcholine binding inhibition (binding assay/biochemical mechanism phrasing) rather than generic “muscarinic receptor antagonism” language.
- It also blends mechanism with topical application and, for M3, respiratory delivery via inhalation devices.
That combination increases enforcement leverage against product characterization disputes, because multiple claim levers (mechanism, receptor, route, site, and indications) can align.
Timeline: when does US 8,309,572 lose exclusivity?
A precise loss-of-exclusivity date cannot be determined from the provided claim text alone. The terminal term depends on:
- the earliest effective priority date of the family,
- whether the patent is subject to PTA,
- and whether any additional exclusivities apply via FDA (not predictable from claims alone).
So this element is not computable with your input.
Key Takeaways
- US 8,309,572 is a method-of-use patent built around Formula (I) chemical matter used to inhibit acetylcholine binding to acetylcholine receptors, with a primary enforcement focus on M3 muscarinic receptor (claim 21) and respiratory tract inhalation use (claims 25, 27–31).
- The claim scope is driven by three high-value levers: (i) Markush breadth of Formula (I) substituents (m 1–15, t 0–5, p 0–4, wide R-group sets), (ii) route/site constraints (topical; respiratory tract; inhalation via mouth/nose), and (iii) counterion constraints in dependent claims.
- Design-around is most credible only through moving the active outside Formula (I) or potentially by changing delivery route/device so it does not meet “inhalation by mouth or nose” or the specified dispenser types. Changing salt may reduce dependent claim overlap but does not automatically remove exposure because the independent method requires only “pharmaceutically acceptable anion.”
- Generic risk concentrates on products that place Formula (I) actives into the respiratory mucosa via inhalation using the enumerated inhaler categories.
FAQs
-
Does US 8,309,572 require systemic administration or is local respiratory delivery sufficient?
It requires “topical application” and, in M3 dependent claims, “respiratory tract” contact, including inhalation by mouth or nose.
-
Which dependent claims most directly target inhaler technology for respiratory delivery?
Claims 31 (inhalation device categories), 28 (inhalation via mouth or nose), 29–30 (mouth vs nose), and 35 (dispenser examples tied to the method).
-
Can a competitor avoid infringement by changing from bromide/iodide to another salt?
Dependent claims (2–4, 22–24, 42) narrow to specific anions, but independent claims require a “pharmaceutically acceptable anion,” so a non-enumerated salt does not automatically defeat independent claim coverage.
-
What is the cleanest non-infringement strategy under these claims?
Use actives that do not fall within Formula (I) as claimed. Route-only changes are narrower leverage because the claims already include multiple anatomical and route subtypes (mouth, nose, inhalation).
-
Are the treated indications limited or broad?
Indication language is broad in the respiratory disease picklist (claims 32, 36–41), covering COPD/chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis.
References
(No external sources were provided in your prompt, and none are cited.)
More… ↓
⤷ Start Trial
|
